deltatrials
Active Not Recruiting PHASE2 INTERVENTIONAL 3-arm NCT06550128

Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB).

Randomized, Multi-center Phase II Study to Evaluate the Efficacy and Safety of AHB-137 in HBeAg-negative CHB Subjects Under Stable Nucleos(t)Ide Analogue (NA) Treatment

Sponsor: Ausper Biopharma Co., Ltd.

Conditions Hepatitis B, Chronic
Interventions AHB-137 AHB-137 (16weeks) AHB-137 and Placebo
Updated 5 times since 2024 Last updated: Nov 21, 2025 Started: Jul 10, 2024 Primary completion: Feb 2, 2026 Completion: Jun 30, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Hepatitis B, Chronic and is currently ongoing. Ausper Biopharma Co., Ltd. leads this study, which shows 5 recorded versions since 2024 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

~Sep 2024 – ~Dec 2024 · 3 months · monthly snapshotRecruiting~Dec 2024 – ~May 2025 · 5 months · monthly snapshotActive Not Recruiting~May 2025 – ~Nov 2025 · 6 months · monthly snapshotActive Not Recruiting~Nov 2025 – ~Dec 2025 · 30 days · monthly snapshot~Dec 2025 – present · 7 months · monthly snapshotActive Not Recruiting

Change History

5 versions recorded

  1. Dec 2025 — Present [monthly]

    Active Not Recruiting PHASE2

  2. Nov 2025 — Dec 2025 [monthly]

    Active Not Recruiting PHASE2

  3. May 2025 — Nov 2025 [monthly]

    Active Not Recruiting PHASE2

  4. Dec 2024 — May 2025 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  5. Sep 2024 — Dec 2024 [monthly]

    Recruiting PHASE2

    First recorded

Jul 2024

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Ausper Biopharma Co., Ltd.
Data source: Ausper Biopharma Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations